Altimmune, Inc. · NASDAQ:ALT
Altimmune — Technical Presentation (November 2023)
19 slides from Altimmune's technical presentation, Nov 30, 2023
Slide 1: MOMENTUM—Pemvidutide Phase 2 Obesity Trial Topline Week 48 Results
MOMENTUM—Pemvidutide Phase 2 Obesity Trial Topline Week 48 Results 30 November 2023 NASDAQ: ALT
Slide 2: Forward-looking statements
Forward-looking statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not l
Slide 3: MOMENTUM Trial
MOMENTUM Trial • Phase 2, 48-week trial of pemvidutide, a balanced (1:1) GLP-1/glucagon dual receptor agonist, in 391 subjects with overweight or obesity • Randomized 1:1:1:1 to 1 of 4 treatment arms, stratified by gender and baseline BMI, with standard lifestyle interventions • No or rapid (4 week)
Slide 4: Study Population—Key Eligibility Criteria
Study Population—Key Eligibility Criteria • Men and women ages 18-75 years • BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with at least one obesity-related comorbidity - History of cardiovascular disease - Hypertension - Dyslipidemia - Pre-diabetes - Obstructive sleep apnea • Non-diabetes: HbA1c ≤ 6.5% and fast
Slide 5: Study Endpoints
Study Endpoints Efficacy • Primary endpoint • Relative change from baseline in body weight (%) • Key secondary endpoints • Proportions (%) of subjects achieving weight loss of ≥ 5%, ≥ 10%, ≥ 15% and ≥ 20% body weight • Change from baseline in serum lipids and blood pressure Safety • Adverse events (
Slide 6: Disposition of Subjects
Disposition of Subjects 391 randomized and dosed Placebo Pemvidutide 1.2 mg Pemvidutide 1.8 mg Pemvidutide 2.4 mg N=97 (100.0%) N=98 (100.0%) N=99 (100.0%) N=97 (100.0%) Completed study Completed study Completed study Completed study on study drug on study drug on study drug on study drug N=51 (52.6
Slide 7: Baseline Characteristics of Subjects
Baseline Characteristics of Subjects Treatment Characteristic Placebo 1.2 mg 1.8 mg 2.4 mg (N=97) (N=98) (N=99) (N=97) Age, years mean (SD) 50.3 (13.6) 49.6 (12.3) 50.1 (13.3) 48.5 (13.6) Gender female, N (%) 72 (74.2%) 75 (76.5%) 76 (76.8%) 74 (76.3%) White, N (%) 76 (78.4%) 86 (87.8%) 72 (72.7%) 7
Slide 8: Weight Loss of 15.6% Achieved at Week 48 on 2.4 mg
Weight Loss of 15.6% Achieved at Week 48 on 2.4 mg MEAN WEIGHT LOSS OF 32.2 LBS AND MAXIMAL WEIGHT LOSS OF 87.1 LBS Relative Weight Loss (%) Absolute Weight Loss (lbs) *** p < 0.001 *** p < 0.001 vs. placebo vs. placebo (MMRM) (MMRM) 8 MMRM, mixed model for repeated measures
Slide 9: Weight Loss Continuing at Week 48
Weight Loss Continuing at Week 48 Relative Weight Loss (%) • Near linear trajectory of weight loss on 2.4 mg at 48 weeks • Greater weight loss could potentially be realized with longer durations of treatment 9 MMRM, mixed model for repeated measures
Slide 10: Majority of Subjects Lost ≥ 15% Body Weight on 2.4 mg
Majority of Subjects Lost ≥ 15% Body Weight on 2.4 mg ≥5% ≥10% ≥15% ≥20% Weight Loss Weight Loss Weight Loss Weight Loss ** p < 0.005 *** p < 0.001 **** p < 0.0001 vs. placebo (CMH) 10 CMH, Cochran–Mantel–Haenszel
Slide 11: Robust Weight Loss at All Pemvidutide Doses
Robust Weight Loss at All Pemvidutide Doses OVER 30% OF SUBJECTS LOST 20% OR MORE BODY WEIGHT ON 2.4 MG 11
Slide 12: Significant Reductions in BMI at Week 48
Significant Reductions in BMI at Week 48 Mean BMI BMI Classes Over- Obesity Obesity Obesity Normal weight Class 1 Class 2 Class 3 <25 25-30 30-35 35-40 > 40 • 49% of subjects on 2.4 mg realized a 1-class reduction in BMI • 29% of subjects on 2.4 mg realized a 2-class reduction in BMI • 48% of subjec
Slide 13: Robust Reductions in Serum Lipids at Week 48
Robust Reductions in Serum Lipids at Week 48 * p < 0.05 ** p < 0.005 *** p < 0.001 vs. placebo (ANCOVA) 13 ANCOVA, analysis of covariance
Slide 14: Greater Reductions in Triglycerides, Total and LDL Cholesterol in Subjects with Elevated Baseline Levels
Greater Reductions in Triglycerides, Total and LDL Cholesterol in Subjects with Elevated Baseline Levels * p < 0.05 ** p < 0.005 *** p < 0.001 vs. placebo (ANCOVA) 14 ANCOVA, analysis of covariance
Slide 15: Glucose Homeostasis Maintained
Glucose Homeostasis Maintained 15
Slide 16: Improvements in Blood Pressure without Clinically Meaningful Increases in Heart Rate at Week 48
Improvements in Blood Pressure without Clinically Meaningful Increases in Heart Rate at Week 48 Blood Blood Pressure Pressure Heart Rate Heart Rate 16 MMRM, mixed model for repeated measures
Slide 17: Overview of Adverse Events (AEs)
Overview of Adverse Events (AEs) Treatment Characteristic Placebo 1.2 mg 1.8 mg 2.4 mg (N=97) (N=98) (N=99) (N=97) SAEs related to study drug N (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.0%) AEs leading to study drug discontinuation All AEs leading to discontinuation N (%) 6 (6.2%) 5 (5.1%) 19 (19.2%) 19 (
Slide 18: MOMENTUM Trial—Week 48 Summary
MOMENTUM Trial—Week 48 Summary Efficacy • Robust mean weight loss of 15.6% on pemvidutide 2.4 mg at Week 48 • Mean and maximal weight losses of 32.2 lbs and 87.1 lbs, respectively, on 2.4 mg at Week 48 • Over 30% of subjects lost 20% or more body weight on 2.4 mg at Week 48 • Continued weight loss o
Slide 19: Questions pertaining to this presentation
Questions pertaining to this presentation: Rich Eisenstadt, CFO reisenstadt@altimmune.com 19 NASDAQ: ALT